#Mirvetuximab soravtansine-gynx now #FDA approved for FRα +ve, platinum-resistant epithelial ovarian, Fallopian tube, or 1° peritoneal Ca post 1-3L of Rx.
- Assay-Ventana FOLR1 (FOLR-2.1)
- #SORAYA: Ph3, n=106, ORR 31.7%, CR:4.8%, mDOR of 6.9 mos
#Mirvetuximab #FDA #SORAYA #oncology #OncEd #GYNSM #CME #AntibodyDrugConjugate